Characterization of patients admitted to PICU due to febrile neutropenia Clínica Prevenir Barranquilla 2015 –2016
Caracterización de los pacientes que ingresan a UCIP por neutropenia febril Clínica Prevenir Barranquilla 2015 –2016
dc.creator | Medina Caicedo, Malvin | |
dc.creator | Ramos Castro, Jose | |
dc.date.accessioned | 2022-09-28T17:28:58Z | |
dc.date.available | 2022-09-28T17:28:58Z | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3689562 | |
dc.language | spa | |
dc.publisher | Universidad Libre | |
dc.relation | Revistas - Ciencias de la Salud | |
dc.relation | https://revistas.unilibre.edu.co/index.php/biociencias/article/view/2142/1630 | |
dc.relation | /*ref*/Pérez J. Neutropenia febril en pediatría. CCAP Precob SCP. 2011. (12)1:33-45. | |
dc.relation | /*ref*/Lane S, Kohler J. The management of febrile neutropenia. Current Paediatrics 2005; 15: 400-405 | |
dc.relation | /*ref*/Santolaya ME, Rabagliati R, Bidart T, Paya E, Guzman AM, Morales R et al. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol 2005;22 Suppl 2:S79-113 | |
dc.relation | /*ref*/Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011 February 15;52(4):e56-e93 | |
dc.relation | /*ref*/Jaramillo C, Valencia I, Aristizábal M. Neutropenia febril en pacientes pediátricos: un enfoque diagnóstico y terapéutico Iatreia, 2009; 22(3): 235-245 | |
dc.relation | /*ref*/Lai HP, Hsueh PR, Chen YC, Lee PI, Lu CY, Lu MY, et al. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan. J Microbiol Immunol Infect 2003; 36: 197-202. | |
dc.relation | /*ref*/Hughes WT, Armstron D, Bodey GP, Bow EJ, Brown EA, Calandra T, et al. 2002 Guidelines for the use for antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51. | |
dc.relation | /*ref*/Amman RA, Aebi C, Hirt A. Fever in neutropenia in children and adolescents: Evolution over time of main characteristics in a single center, 1993-2001. Support Care Cancer. 2004. (12):826-32 | |
dc.relation | /*ref*/López P, López E. Neutropenia febril en pediatría. Infectio 2008;12(1):64-71. | |
dc.relation | /*ref*/Comité Nacional de Infectologia Pediátrica. [Consensus on management of children with cancer, neutropenia and fever: Update 2008-2009]. Archivos argentinos de pediatría. 2010;108(2):e47–70. | |
dc.relation | /*ref*/De Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21 (5):v252–6. | |
dc.relation | /*ref*/Guzmán P, Ruiz J. Neutropenia febril en Pediatría: ¿qué punto de corte usar?. Pediatría. 2012; 45(3):195-202 | |
dc.relation | /*ref*/Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer. 1996;77(4):791-8. | |
dc.relation | /*ref*/Bate J, Gibson F, Johnson E, Selwood K, Skinner R, Chisholm J, et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Archives of disease in childhood Education and practice edition. 2013;98(2):73-5 | |
dc.relation | /*ref*/Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51 | |
dc.relation | /*ref*/Phillips RS, Wade R, Lehrnbecher T, Stewart L a, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC medicine. BioMed Central Ltd; 2012 Jan;10(1):6. | |
dc.relation | /*ref*/Rincón C. Caracterización de episodios de neutropenia febril en niños con cáncer en la Fundación Hospital de la Misericordia. Uni Nacional. 2013; 1-71 | |
dc.relation | /*ref*/Departamento de estadística, Clínica Prevenir Bonadonna, 2016. | |
dc.relation | /*ref*/Paganini H, Santolaya E, Álvarez M, Araña M, Arteaga R, Bonilla A et al. Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer: Consenso de la Sociedad Latinoamericana de Infectologia Pediátrica. Rev. chil. infectol. 2011; 28(1):10-38. | |
dc.relation | /*ref*/Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities change of the currently isolated pathogens. Clin Infect Dis 2004; 39: S25-S31. | |
dc.relation | /*ref*/Marchetti O, Calandra T. Infections in neutropenic cancer patients. Lancet 2002; 359: 723-5 | |
dc.relation | /*ref*/Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003; 37: 1144-5 | |
dc.relation | /*ref*/Laurichesse H, Romaszko JP, Nguyen LT, Souweine B, Poirier V, Guólon D. Clinical characteristics and outcome of patients with invasive pneumococcal disease Puy de Dóme France1994-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 299-308 | |
dc.relation | /*ref*/Zaoutis TE, Roilides E, Chiou CC, Buchanan WL, Knudsen TA, Sarkisova TA. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26: 723-7 | |
dc.relation | /*ref*/Velasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27: 1071-8 | |
dc.relation | /*ref*/Ramphal R, Grant RM, Dzolganovski B, Constantin J, Tellier R, Allen U. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J 2007; 26: 700-4 | |
dc.relation | /*ref*/Tager FM, Zolezzi RP, Folatre BI, Navarrete CM, Rojas PJ. Respiratory virus infections in children with acute lymphoblastic leukemia and febrile neutropenia: a prospective study. Rev Chil Infectol 2006; 23: 118-23 | |
dc.relation | /*ref*/Rackoff W, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-24 | |
dc.relation | /*ref*/Klaasen RJ, Goodman TR, Pham B, Doyle JJ. Low risk prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-9 | |
dc.relation | /*ref*/Santolaya ME, Alvarez A, Becker A, Cofré J, Enríquez N, O'Ryan M. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cáncer, neutropenia and fever. J Clin Oncol 2001; 19: 3415-21 | |
dc.relation | /*ref*/Santolaya ME, Alvarez A, Avilés CL, Becker A, Cofré J, Enríquez N. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis 2002; 35: 678- 83 | |
dc.relation | /*ref*/Santolaya ME, Alvarez AM, Avilés CL, Becker A, King A, Mosso C. Predictors of severe sepsis not clinically apparent during the first twenty four hours of hospitalization in children with cancer neutropenia and fever: a prospective multicenter trial. Pediatr Infect Dis J 2008; 27: 538-43 | |
dc.relation | /*ref*/Basu SK, Fernández ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005; 23: 7958-66. | |
dc.relation | /*ref*/Paganini H, Aguirre C, Puppa G, Garbini C, Javier R G, Ensinck G. A prospective, multicentric screening system to predict mortality in febrile neutropenic children with cancer. Cancer 2007; 109: 2572-9. | |
dc.relation | /*ref*/Santolaya ME, Alvarez A, Becker A, Avilés CL, Becker A, Mosso C. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenia episode. Pediatr Infect Dis J 2007; 26: 794-8 | |
dc.relation | /*ref*/Rivas R. Consenso mexicano para el abordaje diagnóstico y terapéutico del paciente con neutropenia febril. Rev Hematol Mex 2014;15 (2):207-268 | |
dc.relation | /*ref*/Suárez A, Casas C, González O. Asociación entre el tiempo para iniciar la administración de los antibióticos y desenlaces en pacientes con neutropenia febril. Tesis Unimilitar Nueva Granada. 2016: 1-34 | |
dc.relation | /*ref*/Suárez D, Álvarez M, Gómez J, Carrasco M, Burbano D. Caracterización clínica y de laboratorio de pacientes con neutropenia febril en un hospital pediátrico en Pasto-Colombia. Pediatr. 2016;49(2):48–53 | |
dc.relation | /*ref*/Vizcaíno H. Caracterización clínica y epidemiológica de los pacientes pediátricos oncológicos con neutropenia febril. Uni de Cartagena, 2014:1-24 | |
dc.relation | /*ref*/Navarro J, Sánchez W. Factores de riesgo de ingreso a UCI en pacientes con neutropenia febril, Clínica prevenir Barranquilla y Fundación Hospital Universitario Metropolitano, enero – octubre de 2011. Tesis de grado UniMetro. 2012. | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.rights | Atribución-NoComercial-SinDerivadas 2.5 Colombia | |
dc.rights | Derechos de autor 2017 Revista Biociencias | |
dc.rights | https://creativecommons.org/licenses/by/4.0/deed.es | |
dc.source | Biociencias; Vol 12 No 2 (2017): Biociencias; 17-33 | |
dc.source | Biociencias; Vol. 12 Núm. 2 (2017): Biociencias; 17-33 | |
dc.source | 2390-0512 | |
dc.source | 0124-0110 | |
dc.title | Characterization of patients admitted to PICU due to febrile neutropenia Clínica Prevenir Barranquilla 2015 –2016 | |
dc.title | Caracterización de los pacientes que ingresan a UCIP por neutropenia febril Clínica Prevenir Barranquilla 2015 –2016 |